IONS · ISSUER CIK 874015
IONIS PHARMACEUTICALS INC
Between Jul 31, 2026 and Oct 28, 2026, 7 IONIS PHARMACEUTICALS INC insiders reported $1.1M of open-market purchases and $61K of sales on SEC Form 4. The largest buyer was Hayden Michael R (Director), with $1.1M.
↗7 insiders filed
Original Form 4 filings from Jul 31, 2026 to Oct 28, 2026. 0 of 2 sales were reported under a 10b5-1 plan.
$1.1MInsider buying
$61KInsider selling
+$997KNet open-market
Oct 19, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 19, 202621:40 | Oct 16, 2026 | IONS | EVP, Chief Human Resources Ofc | S · Sell | $43.54 | −1,357 | 17,811 | -7% | −$59K | ||
| Oct 19, 202621:40 | Oct 15, 2026 | IONS | EVP, Chief Human Resources Ofc | M · Exercise | — | +2,820 | 19,168 | +17% | — | ||
| Oct 19, 202621:40 | Oct 16, 2026 | IONS | EVP Research | S · Sell | $43.54 | −53 | 390 | -12% | −$2K | ||
| Oct 19, 202621:40 | Oct 15, 2026 | IONS | EVP Research | M · Exercise | — | +125 | 443 | +39% | — | ||
| Sep 2, 202620:32 | Aug 31, 2026 | IONS | EVP, Chief Scientific Officer | J · Other | $51.31 | +110 | 60,128 | +0% | $6K | ||
| Sep 2, 202620:22 | Aug 31, 2026 | IONS | EVP CLO & General Counsel | J · Other | $51.31 | +63 | 59,205 | +0% | $3K | ||
| Sep 2, 202620:22 | Aug 31, 2026 | IONS | Chief Executive Officer, Director | J · Other | $51.31 | +98 | 242,760 | +0% | $5K | ||
| Sep 2, 202620:22 | Aug 31, 2026 | IONS | EVP, Corp and Development Ops | J · Other | $51.31 | +58 | 102,883 | +0% | $3K | ||
| Jul 31, 202616:42 | Jul 31, 2026from Jul 30, 2026 | IONS | Director | P · Buy | $52.94 | +20,000 | 24,000 | +500% | +$1.1M | -38.7% | -15.2% |